GLAXOSMITHKLINE PHARMACEUTICALS
|
GLAXOSMITHKLINE PHARMACEUTICALS Last 5 Year Balance Sheet History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
EQUITY AND LIABILITIES | |||||
Share Capital | ₹169 Cr | ₹169 Cr | ₹169 Cr | ₹169 Cr | ₹169 Cr |
Equity - Authorised | ₹180 Cr | ₹180 Cr | ₹180 Cr | ₹180 Cr | ₹180 Cr |
Equity - Issued | ₹169 Cr | ₹169 Cr | ₹169 Cr | ₹169 Cr | ₹169 Cr |
Equity Paid Up | ₹169 Cr | ₹169 Cr | ₹169 Cr | ₹169 Cr | ₹169 Cr |
Equity Shares Forfeited | - | - | - | - | - |
Adjustments to Equity | - | - | - | - | - |
Preference Capital Paid Up | - | - | - | - | - |
Face Value | ₹10.00 | ₹10.00 | ₹10.00 | ₹10.00 | ₹10.00 |
Share Warrants & Outstandings | ₹-9.01 Cr | ₹-1.68 Cr | - | - | - |
Total Reserves | ₹1,617 Cr | ₹1,574 Cr | ₹2,494 Cr | ₹1,309 Cr | ₹1,651 Cr |
Securities Premium | - | - | - | - | - |
Capital Reserves | ₹-19 Cr | ₹-19 Cr | ₹-19 Cr | ₹-19 Cr | ₹1.71 Cr |
Profit & Loss Account Balance | ₹876 Cr | ₹829 Cr | ₹1,743 Cr | ₹556 Cr | ₹876 Cr |
General Reserves | ₹779 Cr | ₹779 Cr | ₹779 Cr | ₹779 Cr | ₹779 Cr |
Other Reserves | ₹-19 Cr | ₹-14 Cr | ₹-8.43 Cr | ₹-6.58 Cr | ₹-4.53 Cr |
Reserve excluding Revaluation Reserve | ₹1,617 Cr | ₹1,574 Cr | ₹2,494 Cr | ₹1,309 Cr | ₹1,651 Cr |
Revaluation reserve | - | - | - | - | - |
Shareholder's Funds | ₹1,778 Cr | ₹1,741 Cr | ₹2,663 Cr | ₹1,478 Cr | ₹1,821 Cr |
Minority Interest | - | - | - | - | - |
Long-Term Borrowings | - | - | - | - | - |
Secured Loans | - | - | - | - | - |
Non Convertible Debentures | - | - | - | - | - |
Converible Debentures & Bonds | - | - | - | - | - |
Packing Credit - Bank | - | - | - | - | - |
Inter Corporate & Security Deposit | - | - | - | - | - |
Term Loans - Banks | - | - | - | - | - |
Term Loans - Institutions | - | - | - | - | - |
Other Secured | - | - | - | - | - |
Unsecured Loans | - | - | - | - | ₹0.02 Cr |
Fixed Deposits - Public | - | - | - | - | - |
Loans and advances from subsidiaries | - | - | - | - | - |
Inter Corporate Deposits (Unsecured) | - | - | - | - | - |
Foreign Currency Convertible Notes | - | - | - | - | - |
Long Term Loan in Foreign Currency | - | - | - | - | - |
Loans - Banks | - | - | - | - | - |
Loans - Govt. | - | - | - | - | - |
Loans - Others | - | - | - | - | - |
Other Unsecured Loan | - | - | - | - | ₹0.02 Cr |
Deferred Tax Assets / Liabilities | ₹-146 Cr | ₹-134 Cr | ₹-113 Cr | ₹-103 Cr | ₹-110 Cr |
Deferred Tax Assets | ₹163 Cr | ₹152 Cr | ₹132 Cr | ₹119 Cr | ₹128 Cr |
Deferred Tax Liability | ₹17 Cr | ₹18 Cr | ₹19 Cr | ₹16 Cr | ₹17 Cr |
Other Long Term Liabilities | ₹6.57 Cr | ₹4.14 Cr | ₹9.68 Cr | ₹22 Cr | ₹29 Cr |
Long Term Trade Payables | - | - | - | - | - |
Long Term Provisions | ₹247 Cr | ₹255 Cr | ₹262 Cr | ₹259 Cr | ₹262 Cr |
Total Non-Current Liabilities | ₹108 Cr | ₹125 Cr | ₹159 Cr | ₹179 Cr | ₹180 Cr |
Current Liabilities | - | - | - | - | - |
Trade Payables | ₹625 Cr | ₹428 Cr | ₹579 Cr | ₹466 Cr | ₹357 Cr |
Sundry Creditors | ₹625 Cr | ₹428 Cr | ₹579 Cr | ₹466 Cr | ₹357 Cr |
Acceptances | - | - | - | - | - |
Due to Subsidiaries- Trade Payables | - | - | - | - | - |
Other Current Liabilities | ₹207 Cr | ₹185 Cr | ₹504 Cr | ₹450 Cr | ₹223 Cr |
Bank Overdraft / Short term credit | - | - | - | - | - |
Advances received from customers | ₹7.55 Cr | ₹7.08 Cr | ₹4.35 Cr | ₹4.91 Cr | ₹3.80 Cr |
Interest Accrued But Not Due | - | - | - | - | - |
Share Application Money | - | - | - | - | - |
Current maturity of Debentures & Bonds | - | - | - | - | - |
Current maturity - Others | - | - | - | - | ₹0.15 Cr |
Other Liabilities | ₹200 Cr | ₹178 Cr | ₹499 Cr | ₹445 Cr | ₹219 Cr |
Short Term Borrowings | - | - | - | - | - |
Secured ST Loans repayable on Demands | - | - | - | - | - |
Working Capital Loans- Sec | - | - | - | - | - |
Buyers Credits - Unsec | - | - | - | - | - |
Commercial Borrowings- Unsec | - | - | - | - | - |
Other Unsecured Loans | - | - | - | - | - |
Short Term Provisions | ₹692 Cr | ₹714 Cr | ₹615 Cr | ₹438 Cr | ₹442 Cr |
Proposed Equity Dividend | - | - | - | - | - |
Provision for Corporate Dividend Tax | - | - | - | - | - |
Provision for Tax | ₹299 Cr | ₹296 Cr | ₹296 Cr | ₹164 Cr | ₹161 Cr |
Provision for post retirement benefits | ₹4.78 Cr | ₹4.48 Cr | ₹3.42 Cr | ₹3.36 Cr | ₹3.26 Cr |
Preference Dividend | - | - | - | - | - |
Other Provisions | ₹389 Cr | ₹413 Cr | ₹316 Cr | ₹271 Cr | ₹277 Cr |
Total Current Liabilities | ₹1,525 Cr | ₹1,326 Cr | ₹1,698 Cr | ₹1,355 Cr | ₹1,022 Cr |
Total Liabilities | ₹3,410 Cr | ₹3,193 Cr | ₹4,520 Cr | ₹3,012 Cr | ₹3,023 Cr |
ASSETS | |||||
Gross Block | ₹681 Cr | ₹634 Cr | ₹592 Cr | ₹601 Cr | ₹1,452 Cr |
Less: Accumulated Depreciation | ₹361 Cr | ₹305 Cr | ₹262 Cr | ₹215 Cr | ₹696 Cr |
Less: Impairment of Assets | - | - | - | - | - |
Net Block | ₹320 Cr | ₹329 Cr | ₹329 Cr | ₹386 Cr | ₹757 Cr |
Lease Adjustment A/c | - | - | - | - | - |
Capital Work in Progress | ₹14 Cr | ₹20 Cr | ₹31 Cr | ₹13 Cr | ₹120 Cr |
Non Current Investments | - | - | - | - | - |
Long Term Investment | - | - | - | - | - |
Quoted | - | - | - | - | - |
Unquoted | - | - | - | - | - |
Long Term Loans & Advances | ₹275 Cr | ₹347 Cr | ₹445 Cr | ₹402 Cr | ₹362 Cr |
Other Non Current Assets | ₹1.24 Cr | ₹1.10 Cr | ₹5.45 Cr | ₹7.05 Cr | ₹7.17 Cr |
Total Non-Current Assets | ₹612 Cr | ₹699 Cr | ₹812 Cr | ₹809 Cr | ₹1,248 Cr |
Current Assets Loans & Advances | - | - | - | - | - |
Currents Investments | ₹813 Cr | ₹518 Cr | ₹366 Cr | - | - |
Quoted | ₹813 Cr | ₹518 Cr | ₹366 Cr | - | - |
Unquoted | - | - | - | - | - |
Inventories | ₹525 Cr | ₹460 Cr | ₹535 Cr | ₹547 Cr | ₹483 Cr |
Raw Materials | ₹107 Cr | ₹104 Cr | ₹107 Cr | ₹91 Cr | ₹76 Cr |
Work-in Progress | ₹0.81 Cr | ₹0.95 Cr | ₹0.88 Cr | ₹1.30 Cr | ₹31 Cr |
Finished Goods | ₹99 Cr | ₹101 Cr | ₹151 Cr | ₹128 Cr | ₹92 Cr |
Packing Materials | - | - | - | - | - |
Stores  and Spare | ₹4.00 Cr | ₹3.85 Cr | ₹3.88 Cr | ₹3.79 Cr | ₹3.42 Cr |
Other Inventory | ₹314 Cr | ₹250 Cr | ₹272 Cr | ₹322 Cr | ₹280 Cr |
Sundry Debtors | ₹222 Cr | ₹192 Cr | ₹205 Cr | ₹216 Cr | ₹100 Cr |
Debtors more than Six months | ₹16 Cr | ₹17 Cr | ₹26 Cr | ₹25 Cr | - |
Debtors Others | ₹220 Cr | ₹188 Cr | ₹200 Cr | ₹211 Cr | ₹118 Cr |
Cash and Bank | ₹1,063 Cr | ₹1,156 Cr | ₹2,485 Cr | ₹1,158 Cr | ₹1,083 Cr |
Cash in hand | - | - | - | - | - |
Balances at Bank | ₹1,063 Cr | ₹1,156 Cr | ₹2,485 Cr | ₹1,158 Cr | ₹1,020 Cr |
Other cash and bank balances | - | - | - | - | ₹63 Cr |
Other Current Assets | ₹150 Cr | ₹155 Cr | ₹89 Cr | ₹46 Cr | ₹48 Cr |
Interest accrued on Investments | ₹9.01 Cr | ₹14 Cr | ₹7.64 Cr | ₹7.51 Cr | ₹23 Cr |
Interest accrued on Debentures | - | - | - | - | - |
Deposits with Government | - | - | - | - | - |
Interest accrued and or due on loans | - | - | - | - | - |
Prepaid Expenses | ₹21 Cr | ₹15 Cr | ₹14 Cr | ₹15 Cr | ₹12 Cr |
Other current_assets | ₹121 Cr | ₹126 Cr | ₹68 Cr | ₹24 Cr | ₹13 Cr |
Short Term Loans and Advances | ₹25 Cr | ₹12 Cr | ₹28 Cr | ₹56 Cr | ₹60 Cr |
Advances recoverable in cash or in kind | ₹9.18 Cr | ₹7.84 Cr | ₹19 Cr | ₹10 Cr | ₹17 Cr |
Advance income tax and TDS | - | - | - | - | - |
Amounts due from directors | - | - | - | - | - |
Due From Subsidiaries | - | - | - | - | - |
Inter corporate deposits | - | - | - | - | - |
Corporate Deposits | - | - | - | - | - |
Other Loans & Advances | ₹16 Cr | ₹4.38 Cr | ₹9.73 Cr | ₹46 Cr | ₹43 Cr |
Total Current Assets | ₹2,798 Cr | ₹2,494 Cr | ₹3,708 Cr | ₹2,023 Cr | ₹1,775 Cr |
Net Current Assets (Including Current Investments) | ₹1,273 Cr | ₹1,168 Cr | ₹2,009 Cr | ₹668 Cr | ₹753 Cr |
Miscellaneous Expenses not written off | - | - | - | - | - |
Total Assets | ₹3,410 Cr | ₹3,193 Cr | ₹4,520 Cr | ₹3,012 Cr | ₹3,023 Cr |
Contingent Liabilities | ₹379 Cr | ₹354 Cr | ₹355 Cr | ₹491 Cr | ₹477 Cr |
Total Debt | - | - | - | ₹0.02 Cr | ₹0.18 Cr |
Book Value | - | 102.89 | 157.19 | 87.26 | 107.47 |
Adjusted Book Value | 105.47 | 102.89 | 157.19 | 87.26 | 107.47 |
Compare Balance Sheet of peers of GLAXOSMITHKLINE PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLAXOSMITHKLINE PHARMACEUTICALS | ₹38,370.8 Cr | -3% | -3.4% | 35.3% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹436,103.0 Cr | 1% | 0.7% | 47.3% | Stock Analytics | |
DIVIS LABORATORIES | ₹153,540.0 Cr | -1.1% | -5.8% | 61.7% | Stock Analytics | |
CIPLA | ₹119,196.0 Cr | 0.3% | -1.8% | 19.6% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹112,752.0 Cr | 6% | 11.8% | 20.3% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹97,041.2 Cr | -1.5% | -0.1% | 47% | Stock Analytics |
GLAXOSMITHKLINE PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLAXOSMITHKLINE PHARMACEUTICALS | -3% |
-3.4% |
35.3% |
SENSEX | -2.7% |
-0.8% |
9.9% |
You may also like the below Video Courses